Skip to content

Opus Genetics IRD Forfeited (in dollars per share)

Forfeited (in dollars per share) at other companies

Alto Ingredients, Inc. logo
Alto Ingredients, Inc.ALTO
$1.59-26.4%
NVE Corporation logo
NVE CorporationNVEC
$14.94-34.4%
DJT
Trump Media & Technology GroupDJT
$0.00
Southern First Bancshares logo
Southern First BancsharesSFST
$40.74+7.4%
Norwood Financial logo
Norwood FinancialNWFL
29-3.3%
Accenture logo
AccentureACN
$345.82+18.5%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's forfeited (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's forfeited (in dollars per share)?
Opus Genetics (IRD) reported forfeited (in dollars per share) of $0.00 in Q1 2026.
What does forfeited (in dollars per share) mean?
The weighted average grant date fair value of equity instruments, excluding options, that were forfeited during the period. This metric quantifies the value of compensation that was reversed due to non-vesting. It is useful for understanding the impact of forfeitures on the company's overall share-based compensation expense.